Scienture announces addition of Arbli to formularies of national health plans

Scienture (SCNX) announced that Arbli Oral Suspension, 10 mg/mL has been added to the formularies of key national payors, expanding access through both multiple commercial coverage and Medicare supplement plans. This inclusion extends availability to over 100 million covered lives across the United States. “The addition of Arbli to major national formularies underscores the confidence health plans have in our products and represents a tangible win for patients who deserve effective and affordable treatment options,” commented Narasimhan Mani, President and co-CEO of Scienture. “Patients covered under these plans will now have more affordable access to Arbli, with lower out-of-pocket costs depending on plan design and utilization management.”